INS and metabolic dysfunction-associated steatotic liver disease: Improve insulin sensitivity and promote fatty acid oxidation. SCFAs, like butyrate, activate AMPK in hepatocytes, reducing lipid accumulation and potentially alleviating hepatic steatosis and steatohepatitis in MASLD